Biotheus Acquired by BioNTech for $950 Million Deal
Deal News | Nov 14, 2024 | Goodwin
Biotheus, a clinical-stage biotechnology firm focused on developing antibodies for oncology and inflammatory conditions, has entered into a definitive agreement to be acquired by BioNTech for an upfront payment of $800 million and additional milestone-based payments of up to $150 million. The transaction, expected to close in the first quarter of 2025, was advised by the Goodwin Life Sciences and M&A team. This acquisition arose from a previous collaboration and exclusive licensing agreement, granting BioNTech extensive rights to develop and commercialize Biotheus' antibody BNT327/PM8002 outside of Greater China. Founded on innovative platforms for antibody discovery, Biotheus has a diversified pipeline with ten programs in clinical development stages. Goodwin's extensive team, led by a cohort of legal advisors, provided counsel on this strategic transaction.
Sectors
- Biotechnology
- Pharmaceuticals
- Mergers and Acquisitions (M&A)
Geography
- Germany – BioNTech is a German biotechnology company, and its acquisition of Biotheus illustrates the international scope of the transaction.
- China – Biotheus is presumably based in China, which is relevant to the geographical aspect of the deal.
- Global – The acquisition involves an exclusive license for global rights outside Greater China, reflecting the broad international implications of the transaction.
Industry
- Biotechnology – Biotheus operates in the biotechnology industry, focusing on the development of novel antibodies for medical needs in oncology and inflammatory diseases.
- Pharmaceuticals – BioNTech's acquisition of Biotheus is relevant to the pharmaceutical sector as it enhances BioNTech's portfolio with new drug development capabilities and assets.
- Mergers and Acquisitions (M&A) – The transaction represents a significant merger and acquisition activity in the biotech sector, with BioNTech expanding its reach and capabilities.
Financials
- 800,000,000 – The upfront cash consideration BioNTech will pay to acquire 100% of Biotheus' issued share capital.
- 150,000,000 – Additional performance-based contingent payments dependent on milestone achievements.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Biotheus | Target Company | Company | A clinical-stage biotech firm specializing in the discovery and development of novel antibodies for oncology and inflammatory diseases. |
| BioNTech | Bidding Company / Buyer | Company | A German biotechnology company acquiring Biotheus to expand its portfolio in oncology and inflammation drug research. |
| Goodwin | Legal Advisor | Company | The legal team advising Biotheus on its acquisition by BioNTech, responsible for overseeing the transaction's legal aspects. |
| Wendy Pan, Mayan Katz, Amine Assouad, Kevin Guan | Lead Advisors | People | Key legal advisors from Goodwin leading the team on the acquisition of Biotheus by BioNTech. |